How and when do I transition off GLP-1 medications?

Updated October 2026: reframed for clinicians, updated FDA-approved GLP-1 medications and indications, added the latest withdrawal-trial and meta-analysis evidence, and corrected how long semaglutide and tirzepatide stay in circulation.

GLP-1-based medications are meant to be long-term treatments for type 2 diabetes and obesity. Both are chronic conditions that usually need to be managed over a patient's lifetime, and current guidance reflects this. The 2026 Standards of Care in Overweight and Obesity from the American Diabetes Association's Obesity Association recommend continuing obesity medications after patients reach their treatment goals to maintain health benefits. The World Health Organization's first guideline on GLP-1 therapies, issued in December 2025, conditionally recommends them for long-term treatment of obesity in adults.

Patients still stop, or ask to stop, for many reasons: cost or coverage changes, side effects, planning a pregnancy, or reaching a goal weight. This post summarizes what the evidence says about transitioning off these medications and how to plan the conversation.

Which Medications Are We Talking About?

As of October 2026, FDA-approved GLP-1-based medications include:

• For chronic weight management: semaglutide injection and tablets (Wegovy; the once-daily 25 mg tablet was approved in December 2025), tirzepatide (Zepbound, a dual GIP and GLP-1 receptor agonist), liraglutide (Saxenda) and orforglipron (Foundayo), a once-daily oral small-molecule GLP-1 receptor agonist approved in April 2026.
• For type 2 diabetes: semaglutide (Ozempic, Rybelsus), tirzepatide (Mounjaro), dulaglutide (Trulicity) and liraglutide (Victoza).

Several of these drugs now carry indications beyond weight. Wegovy is also approved to reduce the risk of major adverse cardiovascular events in adults with established cardiovascular disease and obesity or overweight, and to treat noncirrhotic MASH with moderate to advanced liver fibrosis. Zepbound is also approved for moderate to severe obstructive sleep apnea in adults with obesity. For patients taking a drug for one of these indications, stopping may mean giving up more than weight control. For background, see how GLP-1 medications work.

GLP-1 for Diabetes

For patients using a GLP-1-based medication to manage type 2 diabetes, stopping should be a planned clinical decision rather than something the patient does alone. Glycemic control usually worsens after discontinuation: a 2025 meta-analysis of randomized trials found that HbA1c rose by an average of 0.65 percentage points after GLP-1 receptor agonists were stopped in people with type 2 diabetes. Decide whether a different glucose-lowering medication is needed, and increase glucose monitoring during the transition.

GLP-1 for Weight Loss

Many patients use GLP-1-based medications for weight loss and are unsure what to do once they reach their goal weight. Randomized withdrawal trials give a consistent answer: most patients regain weight after stopping.

• STEP 1 extension (semaglutide): one year after stopping semaglutide 2.4 mg, participants had regained about two-thirds of the weight they had lost, and most cardiometabolic improvements moved back toward baseline.
• STEP 4 (semaglutide): after a 20-week run-in, participants switched to placebo regained 6.9% of body weight over 48 weeks, while those who continued semaglutide lost a further 7.9%.
• SURMOUNT-4 (tirzepatide): after 36 weeks of tirzepatide (mean weight loss 20.9%), participants switched to placebo regained 14.0% over 52 weeks, while those who continued lost a further 5.5%.

In the 2025 meta-analysis of randomized trials, stopping GLP-1 receptor agonists in people with obesity was followed by an average weight gain of 5.6 kg, with worsening waist circumference, systolic blood pressure and fasting glucose. Weight regained after discontinuation is mainly fat mass, which matters for patients who also lost lean mass during treatment.

If a patient has lived with obesity for a long time, stopping is generally not recommended. These medications are a long-term treatment for obesity, not a temporary solution.

Is There a Protocol for Stopping?

There is still no validated, guideline-endorsed protocol for discontinuing GLP-1-based medications. A 2026 systematic review concluded that evidence for dietary, behavioral, tapering or pharmacologic transition strategies remains limited, and that discontinuation should be planned as part of chronic obesity care with explicit monitoring and shared decision-making. The best signal so far is for structured exercise: in one randomized trial, participants who combined supervised exercise with liraglutide kept an additional 5.1 kg of weight off one year after both treatments ended, compared with liraglutide alone.

Approaches clinicians are using, none of them yet strongly evidenced, include:

• Dose de-escalation (tapering): stepping down through lower doses rather than stopping abruptly. Preliminary data suggest that tapering semaglutide, combined with lifestyle changes, can sustain weight loss for at least 20 weeks.
• A lower maintenance dose: the ADA obesity standards note that the individualized maintenance dose should balance efficacy, health benefits and tolerability, and may not need to be the maximum approved dose.
• Extended dosing intervals: lengthening the time between injections. This is off-label, and the supporting real-world data are preliminary.

How Long Does the Medication Stay in the System?

The original version of this post understated this. Semaglutide has an elimination half-life of about one week, and according to the Wegovy prescribing information it remains in circulation for about 5 to 7 weeks after the last dose. Tirzepatide's half-life is about 5 days. Appetite and glucose effects therefore fade gradually over several weeks after the final dose, which is often when patients notice increased hunger. Because of semaglutide's long half-life, the Wegovy label advises stopping at least 2 months before a planned pregnancy.

Planning the Transition With Your Patient

• Clarify the reason for stopping. Cost, side effects, pregnancy planning and reaching a goal weight each call for a different plan, and some can be solved without stopping.
• Record a baseline before the last dose: weight, waist circumference, blood pressure, HbA1c or fasting glucose, lipids and, where available, body composition such as appendicular lean mass index.
• Put exercise first. Structured exercise has the strongest evidence for limiting regain and may help preserve lean mass.
• Agree on a re-treatment threshold in advance, such as a defined amount of weight regain or a rise in HbA1c, so restarting is a planned decision rather than a failure.
• Increase follow-up in the months after the final dose, when hunger returns and regain begins.

Monitoring Patients After Discontinuation

Most regain happens between visits, so remote data matter. With Heads Up, data from connected scales, CGMs and wearables (for example Withings and Dexcom) and lab results flow into one longitudinal patient record. Threshold alerts can flag weight regain or rising glucose, and the AI copilot prepares pre-visit briefs that summarize what changed since the last appointment. Learn more about Heads Up for medical weight loss programs.

See how Heads Up tracks your GLP-1 patients before and after discontinuation: request a demo.

References:

1. Wilding, J. P. H., et al., & STEP 1 Study Group. (2022). Weight regain and cardiometabolic effects after withdrawal of semaglutide: The STEP 1 trial extension. Diabetes, Obesity & Metabolism, 24(8), 1553-1564. PubMed
2. Rubino, D., et al. (2021). Effect of continued weekly subcutaneous semaglutide vs placebo on weight loss maintenance in adults with overweight or obesity: The STEP 4 randomized clinical trial. JAMA, 325(14), 1414-1425. PubMed
3. Aronne, L. J., et al. (2024). Continued treatment with tirzepatide for maintenance of weight reduction in adults with obesity: The SURMOUNT-4 randomized clinical trial. JAMA, 331(1), 38-48. PubMed
4. Tzang, C. C., et al. (2025). Metabolic rebound after GLP-1 receptor agonist discontinuation: a systematic review and meta-analysis. eClinicalMedicine, 90, 103680. PubMed
5. Marchetti, M., et al. (2026). Weight regain after discontinuation of GLP-1 and GIP/GLP-1 receptor agonists: A systematic review. Metabolites, 16(10), 757. PubMed
6. Rajjo, T., Bechenati, D., Collantes Hoyos, D. B., & Shah, M. (2026). Long-term use of obesity management medications: challenges and discontinuation strategies. American Family Physician, 113(2), 118-119. AAFP
7. World Health Organization. (2025). WHO issues global guideline on the use of GLP-1 medicines in treating obesity. WHO
8. Wegovy (semaglutide) prescribing information. DailyMed
9. Zepbound (tirzepatide) prescribing information. DailyMed